Aspen Aerogels (NYSE:ASPN) Given New $13.00 Price Target at Barclays

Aspen Aerogels (NYSE:ASPN) had its price objective decreased by research analysts at Barclays from $25.00 to $13.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the construction company’s stock. Barclays‘s price objective suggests a potential upside of 59.80% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Craig Hallum decreased their price target on Aspen Aerogels from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, February 14th. Piper Sandler decreased their price target on Aspen Aerogels from $36.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Roth Mkm reduced their target price on Aspen Aerogels from $22.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 14th. StockNews.com raised Aspen Aerogels to a “sell” rating in a report on Wednesday. Finally, Canaccord Genuity Group reduced their target price on Aspen Aerogels from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.44.

Aspen Aerogels Price Performance

NYSE:ASPN opened at $8.14 on Wednesday. The company has a quick ratio of 2.48, a current ratio of 2.93 and a debt-to-equity ratio of 0.27. The business’s 50-day simple moving average is $11.85 and its two-hundred day simple moving average is $18.22. The stock has a market cap of $667.48 million, a PE ratio of 50.85 and a beta of 2.14. Aspen Aerogels has a 52 week low of $8.02 and a 52 week high of $33.15.

Aspen Aerogels (NYSE:ASPN) last posted its quarterly earnings results on Wednesday, February 12th. The construction company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.11. Aspen Aerogels had a return on equity of 7.49% and a net margin of 2.95%. As a group, analysts forecast that Aspen Aerogels will post 0.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASPN. Sandia Investment Management LP purchased a new position in Aspen Aerogels in the fourth quarter worth about $89,000. AlphaQuest LLC grew its position in Aspen Aerogels by 54.0% in the fourth quarter. AlphaQuest LLC now owns 11,395 shares of the construction company’s stock worth $135,000 after acquiring an additional 3,998 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Aspen Aerogels in the fourth quarter worth about $164,000. Connors Investor Services Inc. purchased a new position in Aspen Aerogels in the fourth quarter worth about $168,000. Finally, Journey Strategic Wealth LLC purchased a new position in Aspen Aerogels in the fourth quarter worth about $178,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.